Listen
YERVOY (ipilimumab), monoclonal antibody
ONCOLOGY - New indication
Opinions on drugs -
Posted on
Jan 21 2015
Reason for request
Extension of indication
No clinical added value demonstrated as a first-line treatment of advanced melanoma in adults when compared with existing therapeutic strategies
- YERVOY now has Marketing Authorisation as first-line treatment for advanced (unresectable or metastatic) melanoma in adult patients.
- In view of the low level of evidence of the submitted studies, YERVOY provided no demonstrable clinical benefit compared with the existing first-line therapeutic strategy for the treatment of advanced melanoma in adults.
Clinical Benefit
| Moderate |
moderate as a first-line treatment for adult patients with advanced (unresectable or metastatic) melanoma, without a B-RAF mutation and in patients with slow progression, good general condition and a life expectancy greater than 3 months. |
Clinical Added Value
| no clinical added value |
In the absence of demonstrated efficacy or safety greater than the existing therapeutic strategy for first-line treatment of advanced melanoma in adults, YERVOY does not provide any improvement in actual benefit (IAB V, non‑existent) |
